Exact Mass: 259.1056

Exact Mass Matches: 259.1056

Found 101 metabolites which its exact mass value is equals to given mass value 259.1056, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Proacacipetalin

3-Butenenitrile, 2-(beta-D-glucopyranosyloxy)-3-methyl-, (S)-

C11H17NO6 (259.1056)


   

Osmaronin

(2E)-3-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

C11H17NO6 (259.1056)


Osmaronin is found in cereals and cereal products. Osmaronin is a constituent of the leaves of Hordeum vulgare (barley). Constituent of the leaves of Hordeum vulgare (barley). Osmaronin is found in barley and cereals and cereal products.

   

Lenalidomide

3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione

C13H13N3O3 (259.0957)


Lenalidomide (initially known as CC-5013 and marketed as Revlimid by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia] C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent > C157388 - Immunomodulatory Imide Drug L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D006133 - Growth Substances > D006131 - Growth Inhibitors D007155 - Immunologic Factors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Fumarycarnitine

(3S)-3-{[(2E)-3-carboxyprop-2-enoyl]oxy}-4-(trimethylazaniumyl)butanoate

C11H17NO6 (259.1056)


Fumarycarnitine is an acylcarnitine. More specifically, it is an fumaric acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Fumarycarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine fumarycarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

Clobenzorex

Benzenemethanamine, 2-chloro, N-(1-methyl-2-phenylethyl)

C16H18ClN (259.1128)


Chemically, clobenzorex is an N-substituted amphetamine analog that is converted to d-amphetamine soon after ingestion. In commercial production, clobenzorex is supplied in 30 mg doses as the hydrochloride salt in green-tinted capsules. The drug gained use as a prescription anorectic in the 1970s; however, adverse reactions were eventually observed, which led to the prohibition of clobenzorex in the United States and certain other countries. Clobenzorex (Asenlix, Dinintel, Finedal, Rexigen) is a stimulant drug of the phenethylamine and amphetamine chemical classes used as an appetite suppressant. The drug is legally distributed in Mexico under the trade name Asenlix by Aventis. A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AA - Centrally acting antiobesity products

   

BEMORADAN

7-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one

C13H13N3O3 (259.0957)


C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor

   

Dibenamine

dibenzyl(2-chloroethyl)amine

C16H18ClN (259.1128)


   

Rhodiocyanoside A

Rhodiocyanoside A

C11H17NO6 (259.1056)


A cyanogenic glycoside that is (2Z)-2-methylbut-2-enenitrile attached to a beta-D-glucopyranosyloxy at position 4. Isolated from Rhodiola quadrifida, it exhibits anti-allergic activity.

   

MCULE-3928088221

MCULE-3928088221

C14H17N3S (259.1143)


   

2-(beta-D-glucopyranosyloxy)-3-methyl-but-2-enenitrile|2-beta-D-Glucopyranosyloxy-3-methyl-crotononitril|2-beta-D-glucopyranosyloxy-3-methyl-crotononitrile|Acacipetalin

2-(beta-D-glucopyranosyloxy)-3-methyl-but-2-enenitrile|2-beta-D-Glucopyranosyloxy-3-methyl-crotononitril|2-beta-D-glucopyranosyloxy-3-methyl-crotononitrile|Acacipetalin

C11H17NO6 (259.1056)


   

Caerulomycin I

Caerulomycin I

C13H13N3O3 (259.0957)


A pyridine alkaloid that is 2,2-bipyridine-6-carboxamide substituted by methoxy groups at position 4 and carbamoyl nitrogen respectively. Isolated from the marine-derived actinomycete Actinoalloteichus cyanogriseus, it exhibits antineoplastic activity.

   

(6E)-3,4-dimethoxy-6-(nitrosomethylidene)-2-pyridin-2-yl-1H-pyridine

(6E)-3,4-dimethoxy-6-(nitrosomethylidene)-2-pyridin-2-yl-1H-pyridine

C13H13N3O3 (259.0957)


   

(E)-2-(hydroxymethylene)butanenitrile beta-D-glucopyranoside|supinanitriloside F

(E)-2-(hydroxymethylene)butanenitrile beta-D-glucopyranoside|supinanitriloside F

C11H17NO6 (259.1056)


   

(Z)-2-(beta-D-glucopyranosyloxy)but-2-enenitrile

(Z)-2-(beta-D-glucopyranosyloxy)but-2-enenitrile

C11H17NO6 (259.1056)


   

(2Z)-4-(beta-D-glucopyranosyloxy)-2-butenenitrile|4-beta-D-pyranoglucosyloxyl-2(Z)-propene-1-nitrile|alliarinoside

(2Z)-4-(beta-D-glucopyranosyloxy)-2-butenenitrile|4-beta-D-pyranoglucosyloxyl-2(Z)-propene-1-nitrile|alliarinoside

C11H17NO6 (259.1056)


   

Lenalidomide

Lenalidomide

C13H13N3O3 (259.0957)


C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent > C157388 - Immunomodulatory Imide Drug L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D006133 - Growth Substances > D006131 - Growth Inhibitors D007155 - Immunologic Factors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

(Z)-2-methyl-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybut-2-enenitrile

(Z)-2-methyl-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybut-2-enenitrile

C11H17NO6 (259.1056)


   

(Z)-2-methyl-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybut-2-enenitrile_major

(Z)-2-methyl-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybut-2-enenitrile_major

C11H17NO6 (259.1056)


   

Osmaronin

(2E)-3-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

C11H17NO6 (259.1056)


   

Asenlix

Benzenemethanamine, 2'-chloro, N-(1-methyl-2-phenylethyl)

C16H18ClN (259.1128)


A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AA - Centrally acting antiobesity products

   

Fumarycarnitine

(3S)-3-{[(2E)-3-carboxyprop-2-enoyl]oxy}-4-(trimethylazaniumyl)butanoate

C11H17NO6 (259.1056)


   

(4-Aminomethyl-pyridin-2-yl)-carbamic acid tert-butyl ester

(4-Aminomethyl-pyridin-2-yl)-carbamic acid tert-butyl ester

C11H18ClN3O2 (259.1087)


   

4-[(1-oxo-3,4-dihydronaphthalen-2-ylidene)methyl]benzonitrile

4-[(1-oxo-3,4-dihydronaphthalen-2-ylidene)methyl]benzonitrile

C18H13NO (259.0997)


   

5-chloro-4-(dimethoxymethyl)-2-(3-methoxypropyl)pyridine

5-chloro-4-(dimethoxymethyl)-2-(3-methoxypropyl)pyridine

C12H18ClNO3 (259.0975)


   

4-(2-HYDROXY-PHENYL)-4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-6-CARBOXYLIC ACID

4-(2-HYDROXY-PHENYL)-4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-6-CARBOXYLIC ACID

C13H13N3O3 (259.0957)


   

Phosphomycin phenylethylamine

Phosphomycin phenylethylamine

C11H18NO4P (259.0973)


   

2-(4-STYRYL-PHENYL)-ETHYLAMINE HYDROCHLORIDE

2-(4-STYRYL-PHENYL)-ETHYLAMINE HYDROCHLORIDE

C16H18ClN (259.1128)


   

2-(1-(TERT-BUTOXYCARBONYL)AZETIDIN-3-YL)MALONIC ACID

2-(1-(TERT-BUTOXYCARBONYL)AZETIDIN-3-YL)MALONIC ACID

C11H17NO6 (259.1056)


   

N-(4-Methoxybenzyl)-4-nitropyridin-2-amine

N-(4-Methoxybenzyl)-4-nitropyridin-2-amine

C13H13N3O3 (259.0957)


   

ciclobendazole

ciclobendazole

C13H13N3O3 (259.0957)


P - Antiparasitic products, insecticides and repellents > P02 - Anthelmintics > P02C - Antinematodal agents > P02CA - Benzimidazole derivatives C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent

   

PSI-6130

PSI-6130

C10H14FN3O4 (259.0968)


PSI-6130 is a potent and selective inhibitor of HCV NS5B polymerase, and inhibits HCV replication with a mean IC50 of 0.6 μM.?

   

6-Methyl-2-(4-vinylphenyl)-1,3,6,2-dioxazaborocane-4,8-dione

6-Methyl-2-(4-vinylphenyl)-1,3,6,2-dioxazaborocane-4,8-dione

C13H14BNO4 (259.1016)


   

1-Phenylvinylboronic acid MIDA ester

1-Phenylvinylboronic acid MIDA ester

C13H14BNO4 (259.1016)


   

6-(4-Methoxybenzyloxy)pyridin-3-ylboronic acid

6-(4-Methoxybenzyloxy)pyridin-3-ylboronic acid

C13H14BNO4 (259.1016)


   

5-HYDRAZINOCARBONYL-1 H-IMIDAZOLE-4-CARBOXYLIC ACID P-TOLYLAMIDE

5-HYDRAZINOCARBONYL-1 H-IMIDAZOLE-4-CARBOXYLIC ACID P-TOLYLAMIDE

C12H13N5O2 (259.1069)


   

1-[4-(4-METHYL-4H-PYRAZIN-1-YL)-3-NITRO-PHENYL]-ETHANONE

1-[4-(4-METHYL-4H-PYRAZIN-1-YL)-3-NITRO-PHENYL]-ETHANONE

C13H13N3O3 (259.0957)


   

4-{[(2-Fluorobenzyl)oxy]methyl}piperidinehydrochloride

4-{[(2-Fluorobenzyl)oxy]methyl}piperidinehydrochloride

C13H19ClFNO (259.1139)


   

N,N-DIMETHYLANILINE HYDROCHLORIDE

N,N-DIMETHYLANILINE HYDROCHLORIDE

C13H13N3O3 (259.0957)


   

2-fluoro-7,8,9,10-tetrahydro-6h-cyclohepta[b]quinoline-11-carboxylic acid

2-fluoro-7,8,9,10-tetrahydro-6h-cyclohepta[b]quinoline-11-carboxylic acid

C15H14FNO2 (259.1009)


   

2,4-Pyrimidinediamine,6-ethyl-5-(4-nitrophenyl)-

2,4-Pyrimidinediamine,6-ethyl-5-(4-nitrophenyl)-

C12H13N5O2 (259.1069)


   

1H-Imidazole-4,5-dicarboxylic acid 4-[(4-amino-phenyl)-amide] 5-methylamide

1H-Imidazole-4,5-dicarboxylic acid 4-[(4-amino-phenyl)-amide] 5-methylamide

C12H13N5O2 (259.1069)


   

N-(1,3-benzodioxol-5-ylmethyl)-1-(4-fluorophenyl)methanamine

N-(1,3-benzodioxol-5-ylmethyl)-1-(4-fluorophenyl)methanamine

C15H14FNO2 (259.1009)


   

2,5-DIMETHOXY-4-(2-FLUORETHYLTHIO)-PHENYLETHYLAMIN

2,5-DIMETHOXY-4-(2-FLUORETHYLTHIO)-PHENYLETHYLAMIN

C12H18FNO2S (259.1042)


   

2-amino-1,4-diphenylpyrrole-3-carbonitrile

2-amino-1,4-diphenylpyrrole-3-carbonitrile

C17H13N3 (259.1109)


   

ART-CHEM-BB B018031

ART-CHEM-BB B018031

C14H17N3S (259.1143)


   

4(1H)-Pyrimidinone,6-amino-5-(2,2-diethoxyethyl)-2,3-dihydro-2-thioxo-

4(1H)-Pyrimidinone,6-amino-5-(2,2-diethoxyethyl)-2,3-dihydro-2-thioxo-

C10H17N3O3S (259.0991)


   

methyl 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)acetate

methyl 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)acetate

C13H13N3O3 (259.0957)


   

3-methyl-1-phenylpyrazolo[3,4-b]quinoline

3-methyl-1-phenylpyrazolo[3,4-b]quinoline

C17H13N3 (259.1109)


   

(S)-METHYL 2-AMINO-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)PROPANOATE HYDROCHLORIDE

(S)-METHYL 2-AMINO-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)PROPANOATE HYDROCHLORIDE

C12H18ClNO3 (259.0975)


   

Methyl 2-amino-4-(3-methoxyphenyl)pyrimidine-5-carboxylate

Methyl 2-amino-4-(3-methoxyphenyl)pyrimidine-5-carboxylate

C13H13N3O3 (259.0957)


   

dimethylammonium 2-(4-chloro-2-methylphenoxy)propionate

dimethylammonium 2-(4-chloro-2-methylphenoxy)propionate

C12H18ClNO3 (259.0975)


   

4-[2-(pyrimidin-2-ylamino)ethoxy]benzoic acid

4-[2-(pyrimidin-2-ylamino)ethoxy]benzoic acid

C13H13N3O3 (259.0957)


   

3-(4-amino-6-anilino-1,3,5-triazin-2-yl)propanoic acid

3-(4-amino-6-anilino-1,3,5-triazin-2-yl)propanoic acid

C12H13N5O2 (259.1069)


   

N-cyclohexyl-1-benzothiophene-2-carboxamide

N-cyclohexyl-1-benzothiophene-2-carboxamide

C15H17NOS (259.1031)


   

2-(3-Carbethoxy-4-hydroxypyrrolidin-2-on-1-yl)ethyl acetate

2-(3-Carbethoxy-4-hydroxypyrrolidin-2-on-1-yl)ethyl acetate

C11H17NO6 (259.1056)


   

4-ETHOXY-1-NAPHTHOIC ACID

4-ETHOXY-1-NAPHTHOIC ACID

C11H17NO6 (259.1056)


   

N-Benzoylhistidine

N-Benzoylhistidine

C13H13N3O3 (259.0957)


   

N-(2-Fluoro-5-Methylphenyl)-4-MethoxybenzaMide, 97\\%

N-(2-Fluoro-5-Methylphenyl)-4-MethoxybenzaMide, 97\\%

C15H14FNO2 (259.1009)


   

N-(2-Fluoro-4-Methylphenyl)-4-MethoxybenzaMide, 97\\%

N-(2-Fluoro-4-Methylphenyl)-4-MethoxybenzaMide, 97\\%

C15H14FNO2 (259.1009)


   

ethyl 8-cyano-7-Methoxy-2-MethyliMidazo[1,2-a]pyridine-3-carboxylate

ethyl 8-cyano-7-Methoxy-2-MethyliMidazo[1,2-a]pyridine-3-carboxylate

C13H13N3O3 (259.0957)


   

4-Fluoro-N,N-diisopropylbenzenesulfonamide

4-Fluoro-N,N-diisopropylbenzenesulfonamide

C12H18FNO2S (259.1042)


   

N-(4-Methoxybenzyl) 4-fluorobenzamide

N-(4-Methoxybenzyl) 4-fluorobenzamide

C15H14FNO2 (259.1009)


   

trans-2-Phenylvinylboronic acid MIDA ester

trans-2-Phenylvinylboronic acid MIDA ester

C13H14BNO4 (259.1016)


   

8-(MORPHOLIN-4-YL)-5-NITROQUINOLINE

8-(MORPHOLIN-4-YL)-5-NITROQUINOLINE

C13H13N3O3 (259.0957)


   

Dibenamine

Dibenamine

C16H18ClN (259.1128)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists

   

3-(3,4-Dimethylanilino)-1-thiophen-2-yl-1-propanone

3-(3,4-Dimethylanilino)-1-thiophen-2-yl-1-propanone

C15H17NOS (259.1031)


   

(3R)-3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione

(3R)-3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione

C13H13N3O3 (259.0957)


   

Clobenzorexum

Clobenzorexum

C16H18ClN (259.1128)


C78272 - Agent Affecting Nervous System > C29728 - Anorexiant

   

Clobenzorex

N-[(2-chlorophenyl)methyl]-1-phenylpropan-2-amine

C16H18ClN (259.1128)


A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AA - Centrally acting antiobesity products

   

BEMORADAN

BEMORADAN

C13H13N3O3 (259.0957)


C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor

   

caerulomycin C

caerulomycin C

C13H13N3O3 (259.0957)


A pyridine alkaloid that is 2,2-bipyridine substituted by methoxy groups at positions 3 and 4 and a (E)-(hydroxyimino)methyl group at position 6. Isolated from the marine-derived actinomycete Actinoalloteichus cyanogriseus, it exhibits antineoplastic activity.

   

1-Methyl-3-phenylpyrazino[1,2-a]benzimidazole

1-Methyl-3-phenylpyrazino[1,2-a]benzimidazole

C17H13N3 (259.1109)


   

3-phenyl-4-(phenylethynyl)-1H-pyrazol-5-amine

3-phenyl-4-(phenylethynyl)-1H-pyrazol-5-amine

C17H13N3 (259.1109)


   

2-[[(4-Methyl-1-pyrazolyl)-oxomethyl]amino]benzoic acid methyl ester

2-[[(4-Methyl-1-pyrazolyl)-oxomethyl]amino]benzoic acid methyl ester

C13H13N3O3 (259.0957)


   

(2r,3ar,7ar)-2-[(2s)-2-Amino-3-Hydroxy-3-Oxo-Propyl]-3,3a,5,6,7,7a-Hexahydrofuro[4,5-B]pyran-2-Carboxylic Acid

(2r,3ar,7ar)-2-[(2s)-2-Amino-3-Hydroxy-3-Oxo-Propyl]-3,3a,5,6,7,7a-Hexahydrofuro[4,5-B]pyran-2-Carboxylic Acid

C11H17NO6 (259.1056)


   

O-fumarylcarnitine

O-fumarylcarnitine

C11H17NO6 (259.1056)


   

O-fumaryl-L-carnitine

O-fumaryl-L-carnitine

C11H17NO6 (259.1056)


An O-acyl-L-carnitine in which the acyl group is specified as fumaryl.

   

(3Z,6Z,9Z)-dodeca-3,6,9-trien-1-yl sulfate

(3Z,6Z,9Z)-dodeca-3,6,9-trien-1-yl sulfate

C12H19O4S- (259.1004)


An organosulfate oxoanion that is the conjugate base of (3Z,6Z,9Z)-dodeca-3,6,9-trien-1-yl hydrogen sulfate. Isolated from Daphnia pulex, it induces morphological changes of phytoplankton Scenedesmus gutwinskii.

   

3-(2-methylpropylsulfanyl)-5H-[1,2,4]triazino[5,6-b]indol-4-ium

3-(2-methylpropylsulfanyl)-5H-[1,2,4]triazino[5,6-b]indol-4-ium

C13H15N4S+ (259.1017)


   

2,4-Dimethyl-4,4A-dihydro-1H-(1,3,5)triazino(1,2-A)quinoline-1,3,6(2H,5H)-trione

2,4-Dimethyl-4,4A-dihydro-1H-(1,3,5)triazino(1,2-A)quinoline-1,3,6(2H,5H)-trione

C13H13N3O3 (259.0957)


   
   
   
   

Dopamine D2 receptor antagonist-1

Dopamine D2 receptor antagonist-1

C14H17N3S (259.1143)


Dopamine D2 receptor antagonist-1 is a negative allosteric modulator (NAM) of the dopamine D2 receptor (D2R) with sub-mM affinity[1].

   

10-amino-3-hydroxy-7-(3-hydroxypropyl)-2,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-1,3,5,8(12),9-pentaen-11-one

10-amino-3-hydroxy-7-(3-hydroxypropyl)-2,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-1,3,5,8(12),9-pentaen-11-one

C13H13N3O3 (259.0957)


   

5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pent-2-enenitrile

5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pent-2-enenitrile

C11H17NO6 (259.1056)


   

3-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

3-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

C11H17NO6 (259.1056)


   

(2e)-2-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-2-enenitrile

(2e)-2-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-2-enenitrile

C11H17NO6 (259.1056)


   

2-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methylidene)butanenitrile

2-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methylidene)butanenitrile

C11H17NO6 (259.1056)


   

n,4-dimethoxy-[2,2'-bipyridine]-6-carboximidic acid

n,4-dimethoxy-[2,2'-bipyridine]-6-carboximidic acid

C13H13N3O3 (259.0957)


   

2-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

2-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

C11H17NO6 (259.1056)


   

(2e)-2-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methylidene)butanenitrile

(2e)-2-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methylidene)butanenitrile

C11H17NO6 (259.1056)


   

3-methyl-2-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-3-enenitrile

3-methyl-2-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-3-enenitrile

C11H17NO6 (259.1056)


   

3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

C11H17NO6 (259.1056)


   

2-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-2-enenitrile

2-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-2-enenitrile

C11H17NO6 (259.1056)


   

(2r)-3-methyl-2-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-3-enenitrile

(2r)-3-methyl-2-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-3-enenitrile

C11H17NO6 (259.1056)


   

(2s)-3-methyl-2-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-3-enenitrile

(2s)-3-methyl-2-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-3-enenitrile

C11H17NO6 (259.1056)


   

(2z)-5-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pent-2-enenitrile

(2z)-5-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pent-2-enenitrile

C11H17NO6 (259.1056)


   

(2z)-2-methyl-4-{[(3r,5s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

(2z)-2-methyl-4-{[(3r,5s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

C11H17NO6 (259.1056)


   

(2e)-2-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

(2e)-2-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

C11H17NO6 (259.1056)


   

(2z)-3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

(2z)-3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-2-enenitrile

C11H17NO6 (259.1056)